Enlitisa (shanghai) Pharmaceutical Co., Ltd.
Clinical trials sponsored by Enlitisa (shanghai) Pharmaceutical Co., Ltd., explained in plain language.
-
New drug TISA-818 shows promise for ARDS patients in early trial
Disease control CompletedThis study tested an experimental drug called TISA-818-Inj in 57 adults with acute respiratory distress syndrome (ARDS), a severe lung condition that makes breathing very difficult. The goal was to see if the drug is safe and whether it can help patients spend fewer days on breat…
Phase: PHASE2 • Sponsor: EnliTISA (Shanghai) Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 07, 2026 18:40 UTC
-
New drug TISA-818 put to the test in healthy volunteers
Knowledge-focused CompletedThis early-stage study tested the safety and tolerability of an experimental drug called TISA-818 in 49 healthy adults. Participants received either the drug or a placebo as a single or multiple daily injections. The goal was to check for side effects and how the drug moves throu…
Phase: PHASE1 • Sponsor: EnliTISA (Shanghai) Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated May 22, 2026 14:01 UTC
-
New drug candidate UP-818-CC passes first safety check in healthy people
Knowledge-focused CompletedThis early-stage study tested the safety and tolerability of a new drug called UP-818-CC in 73 healthy Chinese volunteers. Participants received either a single dose or multiple daily doses of the drug or a placebo by IV infusion. The goal was to check for side effects and how th…
Phase: PHASE1 • Sponsor: EnliTISA (Shanghai) Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated May 20, 2026 11:56 UTC